Q-omics provides the consensus-scored UCHL5 profile across patient tissues and cancer cell-line models. UCHL5 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, UCHL5 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, UCHL5 protein abundance shows 20,928 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, THCA, and GBM as cancer lineages where UCHL5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UCHL5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UCHL5 survival associations across molecular data types. UCHL5 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UCHL5 RNA expression–survival associations across cancer types. High UCHL5 expression shows unfavorable associations in ACC, KIRP, UVM, PAAD and BLCA, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for UCHL5 RNA expression.
This table summarizes UCHL5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for UCHL5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UCHL5 shows lower tumor expression in THCA and higher tumor expression in LUAD, LIHC, BLCA, STAD and HNSC. The THCA box plot shows higher UCHL5 RNA expression in normal versus tumor tissue (log2 FC = −1.197, t-test p < 0.001).
This table shows molecular features associated with UCHL5 in patient tissues and cancer cell lines. In patient samples, UCHL5 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, UCHL5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Lymphoma.
